Dexcom Inc [DXCM] stock is trading at $138.01, up 0.10%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The DXCM shares have gain 2.76% over the last week, with a monthly amount drifted -1.37%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Dexcom Inc [NASDAQ: DXCM] stock has seen the most recent analyst activity on March 12, 2024, when RBC Capital Mkts initiated its Outperform rating and assigned the stock a price target of $165. On April 17, 2023, upgrade upgraded it’s rating to Strong Buy and revised its price target to $138 on the stock. UBS started tracking the stock assigning a Buy rating and suggested a price target of $142 on March 29, 2023. Wolfe Research initiated its recommendation with a Outperform and recommended $121 as its price target on January 26, 2023. Barclays started tracking with a Equal Weight rating for this stock on October 18, 2022, and assigned it a price target of $103. In a note dated October 12, 2022, Jefferies initiated an Buy rating and provided a target price of $125 on this stock.
Dexcom Inc [DXCM] stock has fluctuated between $74.75 and $142.00 over the past year. Currently, Wall Street analysts expect the stock to reach $80.35 within the next 12 months. Dexcom Inc [NASDAQ: DXCM] shares were valued at $138.01 at the most recent close of the market. An investor can expect a potential drop of -41.78% based on the average DXCM price forecast.
Analyzing the DXCM fundamentals
Dexcom Inc [NASDAQ:DXCM] reported sales of 3.62B for the trailing twelve months, which represents a growth of 26.90%. Gross Profit Margin for this corporation currently stands at 0.63% with Operating Profit Margin at 0.17%, Pretax Profit Margin comes in at 0.2%, and Net Profit Margin reading is 0.15%. To continue investigating profitability, this company’s Return on Assets is posted at 0.09, Equity is 0.25 and Total Capital is 0.13. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.25.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 135.19 points at the first support level, and at 132.36 for the second support level. However, for the 1st resistance point, the stock is sitting at 140.04, and for the 2nd resistance point, it is at 142.06.
Dexcom Inc [DXCM] reported earnings per share of $0.5 for its fiscal quarter that ended on 12/31/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $0.43/share, meaning a difference of $0.07 and a surprise factor of 16.30%. By comparison, the stated earnings for the previous quarter ended on 9/30/2023 were $0.5 per share as compared to estimates of $0.34 per share, a difference of $0.16 representing a surprise of 47.10%.
Ratios To Look Out For
For context, Dexcom Inc’s Current Ratio is 2.84. In addition, the Quick Ratio stands at 2.48 and the Cash Ratio stands at 0.36. Considering the valuation of this stock, the price to sales ratio is 14.69, the price to book ratio is 25.71 and price to earnings (TTM) ratio is 105.29.
Transactions by insiders
Recent insider trading involved Dolan Matthew Vincent, EVP Strategy and Corporate Dev, that happened on Apr 15 ’24 when 1990.0 shares were sold. President CEO and Chairman, SAYER KEVIN R completed a deal on Apr 08 ’24 to sell 49633.0 shares. Meanwhile, EVP Chief Legal Officer Brown Michael Jon sold 2624.0 shares on Mar 28 ’24.
